Applied Genetic Tech (AGTC) 12.53 $AGTC AGTC to
Post# of 273257
Posted On: 09/04/2016 7:04:17 AM
Applied Genetic Tech (AGTC) 12.53 $AGTC
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 12, 2016
GlobeNewswire - Thu Sep 01, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter and year ended June 30, 2016 after the market closes on Monday, September 12, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update.
AGTC: 12.53 (-0.13)
Commit To Buy Applied Genetic Technologies Corp At $12.50, Earn 28.2% Annualized Using Options
StockOptionsChannel.com - Fri Aug 26, 10:52AM CDT
Investors eyeing a purchase of Applied Genetic Technologies Corp shares, but cautious about paying the going market price of $13.48/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
AGTC: 12.53 (-0.13)
AGTC Appoints Anne M. VanLent to its Board of Directors
GlobeNewswire - Thu Aug 18, 3:01PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it has appointed Anne M. VanLent to the company's Board of Directors.
AGTC: 12.53 (-0.13)
American Gilsonite to Announce 2nd Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 9:34AM CDT
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the second quarter ended June 30, 2016 to the Company's Intralinks investor site on Friday, August 12, 2016.
AGTC: 12.53 (-0.13)
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16th, 2016
GlobeNewswire - Tue Aug 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16th, 2016 at 1:20pm ET in New York.
AGTC: 12.53 (-0.13)
AGTC and the Medical College of Wisconsin Announce Publication of Natural History Study Data Evaluating Residual Photoreceptor Cone Status in Patients with CNGB3-associated Achromatopsia
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical College of Wisconsin (MCW) today announced the publication of data from studies evaluating the density of cone photoreceptors in patients with CNGB3-associated achromatopsia (ACHM). The peer-reviewed study results appear in the current issue of Investigative Ophthalmology and Visual Science.
AGTC: 12.53 (-0.13)
AGTC to Host Research Day on June 21, 2016 in New York
GlobeNewswire - Thu Jun 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will host a Research Day in New York City on June 21, 2016. AGTC management will be joined by two of its scientific collaborators to discuss the range of ophthalmology clinical endpoints, how they are measured, how they define and describe the vision experienced by the patient, and how results in AGTC's clinical development programs could be reported.
AGTC: 12.53 (-0.13)
AGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the European Commission (EC) has granted an orphan medicinal product designation to its investigational gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
AGTC: 12.53 (-0.13)
Applied Genetic Technologies posts 3Q profit
Automated Insights - Mon May 09, 4:25PM CDT
ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Monday reported fiscal third-quarter net income of $2 million, after reporting a loss in the same period a year earlier.
AGTC: 12.53 (-0.13)
AGTC Announces Financial Results for the Quarter Ended March 31, 2016
GlobeNewswire - Mon May 09, 3:03PM CDT
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended March 31, 2016. The company also announced that it plans to expand its AAV technology platform to address targets that could help treat patients with inherited hearing disorders.
AGTC: 12.53 (-0.13)
Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years
GlobeNewswire - Thu May 05, 6:00AM CDT
Researchers from the University of Massachusetts Medical School today announced new data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for alpha-1 antitrypsin (AAT) deficiency, an inherited genetic defect that results in severe loss of lung function. The investigational gene therapy was developed by Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of gene therapies for the treatment of rare diseases. Study results were presented in a podium session at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting, taking place from May 4 - 7.
AGTC: 12.53 (-0.13)
Novel Investigational Gene-Based Therapy for X-Linked Retinitis Pigmentosa Demonstrates Functional Rescue of Photoreceptor Structure and Function in Canine Model
GlobeNewswire - Mon May 02, 6:00AM CDT
Researchers from the University of Pennsylvania today announced new animal study data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease that causes progressive vision loss in boys and young men. The investigational gene therapy was developed by Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of gene therapies for the treatment of rare diseases. Study results were presented in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 1 - 5.
AGTC: 12.53 (-0.13)
AGTC Announces Participation & Presentations at Upcoming Scientific & Investor Conferences
GlobeNewswire - Fri Apr 29, 6:07AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the company and its collaborators will participate in in the following upcoming conferences.
AGTC: 12.53 (-0.13)
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 9, 2016
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended March 31, 2016 after the market closes on Monday, May 9, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update.
AGTC: 12.53 (-0.13)
AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Leber Congenital Amaurosis (LCA) and Severe Early-Childhood-Onset Retinal Degeneration (SECORD)
GlobeNewswire - Fri Apr 22, 6:01AM CDT
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating an experimental recombinant AAV vector gene delivery in patients with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD), two related retinal diseases caused by mutations in the RPE65 gene that cause severe loss of vision in infancy. Results from the study, entitled "Results at 2 Years after Gene Therapy for RPE65-deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy," were published online in the peer-reviewed journal Ophthalmology and will appear in the April print issue of the journal.
AGTC: 12.53 (-0.13)
American Gilsonite Announces Retirement of Chief Accounting Officer Doug Maughan
PR Newswire - Thu Apr 21, 4:16PM CDT
American Gilsonite Company, Inc. ("American Gilsonite" or "AGC", the world's major supplier of Gilsonite®, today announced the retirement of Chief Accounting Officer, Doug Maughan, effective April 15, 2016. From 2008 to 2015, Maughan served as Chief Financial Officer of American Gilsonite. In November 2015, he announced his anticipated retirement and, since that time, stayed on as the Chief Accounting Officer of the Company.
AGTC: 12.53 (-0.13)
AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia
GlobeNewswire - Wed Apr 20, 6:01AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the publication of two studies that provide support for the Company's planned clinical investigation of its novel investigational gene therapy candidate for treating achromatopsia caused by mutations in the CNGB3 gene. Results, evaluating toxicology and biodistribution profiles in mouse and non-human primate models, were published online in the peer-reviewed journal Human Gene Therapy Clinical Development and appear in the March print issue.
AGTC: 12.53 (-0.13)
New Strong Buy Stocks for April 11th
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 9:04AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
AGTC: 12.53 (-0.13), AYI: 274.00 (-0.08), AMBR: 11.01 (+0.21), BANC: 22.45 (+0.20), APRI: 0.33 (-0.01)
Surging Earnings Estimates Signal Good News for Applied Genetic Technologies (AGTC)
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 7:31AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Applied Genetic Technologies (AGTC) an interesting choice for the investors.
AGTC: 12.53 (-0.13)
Seattle Genetics' (SGEN) Q4 Loss Wider than Expected
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 1:54PM CST
Seattle Genetics' (SGEN) 4Q revenues surpassed expectations with Adcetris sales shooting up 35.5%.
AGTC: 12.53 (-0.13), SGEN: 44.78 (-0.12), ANIK: 47.89 (-0.05)
AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 12, 2016
GlobeNewswire - Thu Sep 01, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter and year ended June 30, 2016 after the market closes on Monday, September 12, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update.
AGTC: 12.53 (-0.13)
Commit To Buy Applied Genetic Technologies Corp At $12.50, Earn 28.2% Annualized Using Options
StockOptionsChannel.com - Fri Aug 26, 10:52AM CDT
Investors eyeing a purchase of Applied Genetic Technologies Corp shares, but cautious about paying the going market price of $13.48/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
AGTC: 12.53 (-0.13)
AGTC Appoints Anne M. VanLent to its Board of Directors
GlobeNewswire - Thu Aug 18, 3:01PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced it has appointed Anne M. VanLent to the company's Board of Directors.
AGTC: 12.53 (-0.13)
American Gilsonite to Announce 2nd Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 9:34AM CDT
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC"
, the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the second quarter ended June 30, 2016 to the Company's Intralinks investor site on Friday, August 12, 2016. AGTC: 12.53 (-0.13)
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16th, 2016
GlobeNewswire - Tue Aug 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16th, 2016 at 1:20pm ET in New York.
AGTC: 12.53 (-0.13)
AGTC and the Medical College of Wisconsin Announce Publication of Natural History Study Data Evaluating Residual Photoreceptor Cone Status in Patients with CNGB3-associated Achromatopsia
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical College of Wisconsin (MCW) today announced the publication of data from studies evaluating the density of cone photoreceptors in patients with CNGB3-associated achromatopsia (ACHM). The peer-reviewed study results appear in the current issue of Investigative Ophthalmology and Visual Science.
AGTC: 12.53 (-0.13)
AGTC to Host Research Day on June 21, 2016 in New York
GlobeNewswire - Thu Jun 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will host a Research Day in New York City on June 21, 2016. AGTC management will be joined by two of its scientific collaborators to discuss the range of ophthalmology clinical endpoints, how they are measured, how they define and describe the vision experienced by the patient, and how results in AGTC's clinical development programs could be reported.
AGTC: 12.53 (-0.13)
AGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the European Commission (EC) has granted an orphan medicinal product designation to its investigational gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
AGTC: 12.53 (-0.13)
Applied Genetic Technologies posts 3Q profit
Automated Insights - Mon May 09, 4:25PM CDT
ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Monday reported fiscal third-quarter net income of $2 million, after reporting a loss in the same period a year earlier.
AGTC: 12.53 (-0.13)
AGTC Announces Financial Results for the Quarter Ended March 31, 2016
GlobeNewswire - Mon May 09, 3:03PM CDT
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended March 31, 2016. The company also announced that it plans to expand its AAV technology platform to address targets that could help treat patients with inherited hearing disorders.
AGTC: 12.53 (-0.13)
Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years
GlobeNewswire - Thu May 05, 6:00AM CDT
Researchers from the University of Massachusetts Medical School today announced new data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for alpha-1 antitrypsin (AAT) deficiency, an inherited genetic defect that results in severe loss of lung function. The investigational gene therapy was developed by Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of gene therapies for the treatment of rare diseases. Study results were presented in a podium session at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting, taking place from May 4 - 7.
AGTC: 12.53 (-0.13)
Novel Investigational Gene-Based Therapy for X-Linked Retinitis Pigmentosa Demonstrates Functional Rescue of Photoreceptor Structure and Function in Canine Model
GlobeNewswire - Mon May 02, 6:00AM CDT
Researchers from the University of Pennsylvania today announced new animal study data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease that causes progressive vision loss in boys and young men. The investigational gene therapy was developed by Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of gene therapies for the treatment of rare diseases. Study results were presented in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 1 - 5.
AGTC: 12.53 (-0.13)
AGTC Announces Participation & Presentations at Upcoming Scientific & Investor Conferences
GlobeNewswire - Fri Apr 29, 6:07AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the company and its collaborators will participate in in the following upcoming conferences.
AGTC: 12.53 (-0.13)
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 9, 2016
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended March 31, 2016 after the market closes on Monday, May 9, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update.
AGTC: 12.53 (-0.13)
AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Leber Congenital Amaurosis (LCA) and Severe Early-Childhood-Onset Retinal Degeneration (SECORD)
GlobeNewswire - Fri Apr 22, 6:01AM CDT
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating an experimental recombinant AAV vector gene delivery in patients with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD), two related retinal diseases caused by mutations in the RPE65 gene that cause severe loss of vision in infancy. Results from the study, entitled "Results at 2 Years after Gene Therapy for RPE65-deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy," were published online in the peer-reviewed journal Ophthalmology and will appear in the April print issue of the journal.
AGTC: 12.53 (-0.13)
American Gilsonite Announces Retirement of Chief Accounting Officer Doug Maughan
PR Newswire - Thu Apr 21, 4:16PM CDT
American Gilsonite Company, Inc. ("American Gilsonite" or "AGC"
, the world's major supplier of Gilsonite®, today announced the retirement of Chief Accounting Officer, Doug Maughan, effective April 15, 2016. From 2008 to 2015, Maughan served as Chief Financial Officer of American Gilsonite. In November 2015, he announced his anticipated retirement and, since that time, stayed on as the Chief Accounting Officer of the Company. AGTC: 12.53 (-0.13)
AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia
GlobeNewswire - Wed Apr 20, 6:01AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the publication of two studies that provide support for the Company's planned clinical investigation of its novel investigational gene therapy candidate for treating achromatopsia caused by mutations in the CNGB3 gene. Results, evaluating toxicology and biodistribution profiles in mouse and non-human primate models, were published online in the peer-reviewed journal Human Gene Therapy Clinical Development and appear in the March print issue.
AGTC: 12.53 (-0.13)
New Strong Buy Stocks for April 11th
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 9:04AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
AGTC: 12.53 (-0.13), AYI: 274.00 (-0.08), AMBR: 11.01 (+0.21), BANC: 22.45 (+0.20), APRI: 0.33 (-0.01)
Surging Earnings Estimates Signal Good News for Applied Genetic Technologies (AGTC)
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 7:31AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Applied Genetic Technologies (AGTC) an interesting choice for the investors.
AGTC: 12.53 (-0.13)
Seattle Genetics' (SGEN) Q4 Loss Wider than Expected
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 1:54PM CST
Seattle Genetics' (SGEN) 4Q revenues surpassed expectations with Adcetris sales shooting up 35.5%.
AGTC: 12.53 (-0.13), SGEN: 44.78 (-0.12), ANIK: 47.89 (-0.05)
(0)
(0)Scroll down for more posts ▼